
To get the Zimmer Biomet stock quote, you can check the company's website or use a financial website such as Yahoo Finance or Google Finance. These websites provide real-time stock quotes and other financial information.
Zimmer Biomet is a leading manufacturer of orthopedic and spine products, and its stock is listed on the New York Stock Exchange under the ticker symbol ZBH.
To stay up-to-date on the latest news and developments affecting Zimmer Biomet's stock, you can also follow the company's investor relations page or sign up for news alerts from reputable financial sources.
Analysts' opinions on Zimmer Biomet's stock can vary, but many have a positive outlook on the company's future prospects.
You might enjoy: Black Rifle Coffee Company Stock Symbol
Financial Performance
Zimmer Biomet's financial performance has been a mixed bag in recent years. The company has seen its sales and earnings slip in some quarters, but it has also had periods of success, such as beating expectations in Q4.
The company's revenue has been steadily increasing, with estimates suggesting it will reach $8,009 USD in 2025 and $9,241 USD in 2028. Zimmer Biomet's revenue has been growing, with estimates suggesting it will reach $8,009 USD in 2025 and $9,241 USD in 2028.
In terms of profitability, Zimmer Biomet's net profit has been steadily increasing, reaching $1,728 USD in 2025 and $2,127 USD in 2028. The company's net profit has been steadily increasing, reaching $1,728 USD in 2025 and $2,127 USD in 2028.
Here is a breakdown of Zimmer Biomet's estimated financial performance for the next few years:
Zimmer Biomet's cash flow has also been a positive aspect of its financial performance, with estimates suggesting it will reach $2,186 USD in 2025 and $2,127 USD in 2028. The company's cash flow has been steadily increasing, with estimates suggesting it will reach $2,186 USD in 2025 and $2,127 USD in 2028.
The company's dividend yield has been steadily decreasing, reaching 0.66% in 2026 and 0.90% in 2027. Zimmer Biomet's dividend yield has been steadily decreasing, reaching 0.66% in 2026 and 0.90% in 2027.
Overall, Zimmer Biomet's financial performance has been a mixed bag, with some quarters seeing success and others seeing decline. However, the company's revenue and net profit estimates suggest a positive outlook for the future.
Here's an interesting read: Medtronic Dividend Yield
Market Data
The current market data for Zimmer Biomet stock is as follows: After-Market price is $109.69, with a decrease of $2.17 (-1.94%) from the previous day's close. The Zacks Rank for Zimmer Biomet stock is #1, indicating a Strong Buy rating.
The Zacks Rank is a timeliness indicator that serves as a predictor for stocks over the next 1 to 3 months, with an average annualized return of 24.30% for Strong Buy stocks. This is significantly higher than the average annualized return of 11.39% for the S&P 500.
Here's a breakdown of the Zacks Rank and its corresponding annualized returns:
Competitors
In the market data landscape, several competitors are vying for attention.
One notable competitor is Bloomberg, a well-established player in the financial data space. They offer a wide range of products and services, including real-time market data, news, and analytics.
Another competitor is Refinitiv, a leading provider of financial market data and infrastructure. They offer a comprehensive suite of products and services, including market data, news, and analytics.
Worth a look: Early Warning Services Stock
S&P Global Market Intelligence is another key competitor, offering a range of products and services, including market data, news, and analytics. Their data is used by many financial institutions and organizations.
These competitors are all major players in the market data space, offering a range of products and services that cater to different needs and requirements.
On a similar theme: Stock Symbol for Subaru
NYSE Delayed Data
The NYSE Delayed Data is a key indicator for investors to keep an eye on. It shows the current price of a stock after the market has closed, which in this case is $109.69 with a -2.17% decline.
The Zacks Rank system is a useful tool for determining the potential success of a stock over the next 1 to 3 months. According to the system, a Strong Buy (Zacks Rank #1) has an annualized return of 24.30%, while a Sell (Zacks Rank #5) has an annualized return of 2.72%.
The Zacks Rank system is based on three trading styles: Value, Growth, and Momentum. Each style has a score, and the VGM Score is the weighted average of these scores. For this stock, the Value Score, Growth Score, Momentum Score, and VGM Score are all A.
Worth a look: System Capital Management Stock
The scores are graded into five groups: A, B, C, D, and F. An A is the best, followed by B, then C, D, and finally F. As an investor, you want to buy stocks with the highest probability of success, which means looking for stocks with a Zacks Rank #1 or #2 and a Score of A or B.
Here's a breakdown of the Zacks Rank system:
The industry with the best average Zacks Rank is considered the top industry, and it would place in the top 1% of Zacks Ranked Industries.
Here's an interesting read: Top Bitcoin Mining Stocks
Frequently Asked Questions
Is Zimmer Biomet a good stock to buy?
According to Wall Street analysts, Zimmer Biomet is a "hold" stock, with a majority of analysts recommending a neutral stance. However, with 7 buy ratings and 2 sell ratings, opinions are divided, and further research may be necessary to make an informed investment decision.
What happened to Zimmer Biomet?
Zimmer Biomet's stock price dropped nearly 9% after the company warned of sales and profit impacts due to a new ERP system implementation. The company expects this transition to affect its 2024 financial performance.
Is Zimmer publicly traded?
Yes, Zimmer Biomet is publicly traded on the New York Stock Exchange (NYSE) and the SIX Swiss Exchange. You can find its shares listed under the ticker symbol ZBH.
Featured Images: pexels.com


